MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 47,775 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 47,775 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $20.03, for a total value of $956,933.25. Following the transaction, the chief executive officer owned 2,877,118 shares of the company’s stock, valued at $57,628,673.54. This trade represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Da Silva Jorge Santos also recently made the following trade(s):

• On Monday, April 13th, Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.23, for a total value of $945,644.79.
• On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.41, for a total value of $1,806,518.07.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX opened at $18.95 on Friday. The company has a market capitalization of $1.39 billion, a PE ratio of -4.90 and a beta of 1.04. The company has a 50 day simple moving average of $18.29 and a two-hundred day simple moving average of $17.03. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). Research analysts anticipate that MoonLake Immunotherapeutics will post -3.71 earnings per share for the current year.

Analyst Ratings Changes

MLTX has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and boosted their price objective for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $12.00 to $40.00 in a research report on Thursday, March 19th. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Finally, Leerink Partners lifted their target price on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of “Hold” and a consensus price target of $24.21.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MLTX. Cormorant Asset Management LP increased its holdings in shares of MoonLake Immunotherapeutics by 118.4% during the fourth quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock valued at $57,405,000 after acquiring an additional 2,361,260 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of MoonLake Immunotherapeutics by 18,782.8% in the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock worth $27,657,000 after purchasing an additional 2,084,888 shares in the last quarter. Logos Global Management LP bought a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth $23,065,000. Weiss Asset Management LP grew its position in MoonLake Immunotherapeutics by 413.1% in the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after purchasing an additional 1,375,367 shares during the period. Finally, Vivo Capital LLC acquired a new stake in MoonLake Immunotherapeutics in the 4th quarter valued at $13,180,000. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.